

Table 3.6
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 1, 2019; Events through March 1, 2019

	MRC Super Cohort¹	SRC Super Cohort²
Number of participants	44174	117634
Mean follow-up (months)	177.3	193.4
Overall cancer	7968 (1.22%)	26121 (1.38%)
Primary cancer		
Breast cancer	2918 (0.45%)	10445 (0.55%)
Invasive breast cancer	2393 (0.37%)	8738 (0.46%)
In situ breast cancer	580 (0.09%)	1859 (0.10%)
Ovarian cancer	273 (0.04%)	1001 (0.05%)
Endometrial cancer ³	330 (0.09%)	1488 (0.13%)
Colorectal cancer	930 (0.14%)	2382 (0.13%)
Other cancer		
Accessory sinus	2 (<0.01%)	12 (<0.01%)
Adrenal gland	4 (<0.01%)	12 (<0.01%)
Anus	28 (<0.01%)	92 (<0.01%)
Appendix	12 (<0.01%)	30 (<0.01%)
Base of tongue	8 (<0.01%)	24 (<0.01%)
Biliary tract, parts of (other/unspecified)	57 (0.01%)	138 (0.01%)
Bladder	245 (0.04%)	769 (0.04%)
Bones/joints/articular cartilage (limbs)	2 (<0.01%)	11 (<0.01%)
Bones/joints/articular cartilage (other)	9 (<0.01%)	19 (<0.01%)
Brain	68 (0.01%)	303 (0.02%)
Cervix	44 (0.01%)	88 (<0.01%)
Central Nervous System (excludes brain)	1 (<0.01%)	4 (<0.01%)
Connective/subcutaneous/soft tissues	43 (0.01%)	147 (0.01%)
Endocrine glands, related structures	0 (0.00%)	4 (<0.01%)
Esophagus	47 (0.01%)	134 (0.01%)
Eye and adnexa	24 (<0.01%)	59 (<0.01%)
Floor of mouth	7 (<0.01%)	10 (<0.01%)
Gallbladder	44 (0.01%)	99 (0.01%)
Genital organs	77 (0.01%)	283 (0.01%)
Gum	6 (<0.01%)	40 (<0.01%)
Heart	4 (<0.01%)	32 (<0.01%)
Kidney	201 (0.03%)	545 (0.03%)
Larynx	21 (<0.01%)	33 (<0.01%)
Leukemia	251 (0.04%)	874 (0.05%)
Liver	98 (0.02%)	227 (0.01%)
Lung	1122 (0.17%)	2985 (0.16%)
Lymph nodes	1 (<0.01%)	2 (<0.01%)
Lymphoma, Hodgkins	22 (<0.01%)	54 (<0.01%)
Lymphoma, non-Hodgkins	383 (0.06%)	1426 (0.08%)
Melanoma of the skin	368 (0.06%)	2177 (0.11%)
Meninges	2 (<0.01%)	5 (<0.01%)
Multiple myeloma	201 (0.03%)	434 (0.02%)
Mycosis fungoides	7 (<0.01%)	20 (<0.01%)
Nasal cavity mid ear	2 (<0.01%)	18 (<0.01%)
Oral (mouth)	7 (<0.01%)	32 (<0.01%)
Other digestive cancer	9 (<0.01%)	43 (<0.01%)
Other lip	7 (<0.01%)	6 (<0.01%)
Palate	7 (<0.01%)	25 (<0.01%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.

Table 3.6 (continued)
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 1, 2019; Events through March 1, 2019

	MRC Super Cohort¹	SRC Super Cohort²
Number of participants	44174	117634
Mean follow-up (months)	177.3	193.4
Pancreas	327 (0.05%)	929 (0.05%)
Parotid gland (Stensen's duct)	14 (<0.01%)	47 (<0.01%)
Peripheral nerves and autonomic nervous	0 (0.00%)	2 (<0.01%)
Peritoneum	53 (0.01%)	172 (0.01%)
Pharynx	11 (<0.01%)	18 (<0.01%)
Pyriform sinus	0 (0.00%)	2 (<0.01%)
Renal pelvis	35 (0.01%)	90 (<0.01%)
Respiratory system, intrathoracic, other	0 (0.00%)	3 (<0.01%)
Salivary glands, major (other/unspecified)	3 (<0.01%)	15 (<0.01%)
Small intestine	40 (0.01%)	118 (0.01%)
Stomach	99 (0.02%)	209 (0.01%)
Thymus	3 (<0.01%)	10 (<0.01%)
Thyroid	103 (0.02%)	395 (0.02%)
Tongue, part of (other/unspecified)	15 (<0.01%)	70 (<0.01%)
Tonsil	2 (<0.01%)	18 (<0.01%)
Trachea	1 (<0.01%)	0 (0.00%)
Ureter	19 (<0.01%)	65 (<0.01%)
Urinary organs (other/unspecified)	9 (<0.01%)	25 (<0.01%)
Uterus, not otherwise specified ³	31 (0.01%)	95 (0.01%)
Other/unknown site of cancer	137 (0.02%)	430 (0.02%)
Other/unknown cancers reported on death form	92 (0.01%)	342 (0.02%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.